AI-driven bioinformatics company Tempus and TScan Therapeutics are collaborating to develop a companion diagnostic test for T-cell receptor (TCR)-engineered T-cell therapies (TCR-T) used in cancer treatment.
The partnership aims to create a screening protocol for TScan's Phase I solid tumor clinical trial, which enables customized mixtures of TCR-Ts to be administered to patients based on tumor antigen positivity and intact HLA expression. Tempus' xT assay, a 648-gene panel, is used to identify patients with HLA loss in the tumor, allowing the selection of appropriate TCR-Ts. The collaboration has the potential to help patients with various solid tumor types by identifying those most likely to respond to TCR-T treatment.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.